SG Americas Securities LLC Trims Stock Holdings in Gilead Sciences, Inc. $GILD

SG Americas Securities LLC cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 36.2% during the second quarter, HoldingsChannel.com reports. The fund owned 43,615 shares of the biopharmaceutical company’s stock after selling 24,796 shares during the quarter. SG Americas Securities LLC’s holdings in Gilead Sciences were worth $4,836,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Gilead Sciences by 2.6% during the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after buying an additional 727,515 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after buying an additional 11,156,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Gilead Sciences by 12.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock worth $1,541,302,000 after buying an additional 1,520,809 shares during the last quarter. Finally, Nuveen LLC acquired a new position in Gilead Sciences in the 1st quarter valued at about $620,415,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on GILD. TD Cowen increased their price objective on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. UBS Group lifted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Rothschild & Co Redburn upped their price objective on shares of Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Finally, Citigroup lifted their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $129.13.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $124.09 on Tuesday. The firm has a market capitalization of $153.96 billion, a P/E ratio of 24.72, a PEG ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a one year low of $86.08 and a one year high of $127.68. The company’s fifty day moving average is $117.61 and its two-hundred day moving average is $113.02. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter last year, the firm posted $2.02 EPS. The business’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $354,240.00. Following the sale, the insider owned 110,193 shares in the company, valued at $13,011,589.44. This represents a 2.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 94,646 shares of company stock valued at $11,311,286 in the last 90 days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.